300146 汤臣倍健
交易中 04-17 14:05:27
资讯
新帖
简况
汤臣倍健：公司希望通过做强主业为投资者创造长期价值
证券之星 · 04-15 18:00
汤臣倍健：公司希望通过做强主业为投资者创造长期价值
汤臣倍健：拟每10股分红4.50元（含税）
证券日报 · 04-13
汤臣倍健：拟每10股分红4.50元（含税）
汤臣倍健：公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能
证券之星 · 04-13
汤臣倍健：公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
证券之星 · 04-13
汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请
汤臣倍健：加速科研成果向具有核心竞争力的产品转化
证券之星 · 04-07
汤臣倍健：加速科研成果向具有核心竞争力的产品转化
股市必读：汤臣倍健（300146）4月3日董秘有最新回复
证券之星 · 04-07
股市必读：汤臣倍健（300146）4月3日董秘有最新回复
汤臣倍健：公司是此项国家标准的起草单位之一
证券之星 · 04-04
汤臣倍健：公司是此项国家标准的起草单位之一
汤臣倍健：2026年计划实现营业收入同比双位数增长
证券之星 · 03-27
汤臣倍健：2026年计划实现营业收入同比双位数增长
汤臣倍健：国家尚未将“降低发生心源性猝死风险”列为可声称的保健功能
证券之星 · 03-27
汤臣倍健：国家尚未将“降低发生心源性猝死风险”列为可声称的保健功能
汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累
证券之星 · 03-27
汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累
营收降、利润增，汤臣倍健“再创业”能否穿越周期
蓝鲸财经 · 03-25
营收降、利润增，汤臣倍健“再创业”能否穿越周期
汤臣倍健：公司坚持在整体战略规划下审慎决策投资并购事项
证券之星 · 03-24
汤臣倍健：公司坚持在整体战略规划下审慎决策投资并购事项
汤臣倍健：研发费用下降主要系委外研发未达预期收到供应商退款
证券之星 · 03-23
汤臣倍健：研发费用下降主要系委外研发未达预期收到供应商退款
股市必读：汤臣倍健年报 - 第四季度单季净利润同比增长42.00%
证券之星 · 03-23
股市必读：汤臣倍健年报 - 第四季度单季净利润同比增长42.00%
汤臣倍健：目前已在东南亚主要国家进行布局
新京报 · 03-22
汤臣倍健：目前已在东南亚主要国家进行布局
汤臣倍健(300146)2月28日股东户数6.46万户，较上期减少4.08%
证券之星 · 03-21
汤臣倍健(300146)2月28日股东户数6.46万户，较上期减少4.08%
汤臣倍健(300146.SZ)发布2025年度业绩，归母净利润7.82亿元，增长19.81%
智通财经 · 03-20
汤臣倍健(300146.SZ)发布2025年度业绩，归母净利润7.82亿元，增长19.81%
汤臣倍健：坚持以消费者需求为导向
证券之星 · 03-18
汤臣倍健：坚持以消费者需求为导向
股市必读：汤臣倍健（300146）3月13日董秘有最新回复
证券之星 · 03-16
股市必读：汤臣倍健（300146）3月13日董秘有最新回复
汤臣倍健：公司将综合考虑对投资者的持续回报及公司经营发展的资金需求等确定利润分配预案
证券之星 · 03-11
汤臣倍健：公司将综合考虑对投资者的持续回报及公司经营发展的资金需求等确定利润分配预案
暂无数据
公司概况
公司名称：
汤臣倍健股份有限公司
所属行业：
食品制造业
上市日期：
2010-12-15
主营业务：
汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司已获得145项原料及配方等发明专利。
发行价格：
110.00
{"stockData":{"symbol":"300146","market":"SZ","secType":"STK","nameCN":"汤臣倍健","latestPrice":11.08,"timestamp":1776405927000,"preClose":11.13,"halted":0,"volume":9722504,"delay":0,"changeRate":-0.0045,"floatShares":1121000000,"shares":1692000000,"eps":0.5388,"marketStatus":"交易中","change":-0.05,"latestTime":"04-17 14:05:27","open":11.13,"high":11.13,"low":10.97,"amount":107000000,"amplitude":0.0144,"askPrice":11.09,"askSize":580,"bidPrice":11.08,"bidSize":715,"shortable":0,"etf":0,"ttmEps":0.5388,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776409200000},"marketStatusCode":2,"adr":0,"adjPreClose":11.13,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":12.24,"lowLimit":10.02,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1691677031,"isCdr":false,"pbRate":1.69,"roa":"--","peRate":20.564217,"roe":"7.18%","epsLYR":0.47,"committee":0.036696,"marketValue":18744000000,"turnoverRate":0.0087,"status":1,"floatMarketCap":12417000000},"requestUrl":"/m/hq/s/300146/tweets","defaultTab":"tweets","newsList":[{"id":"2627283353","title":"汤臣倍健：公司希望通过做强主业为投资者创造长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2627283353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627283353?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:00","pubTimestamp":1776247250,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月15日在投资者关系平台上答复投资者关心的问题。2021年公司市值已经600多亿了。市值受内外部多种因素影响，内因如公司策略有效性和经营表现，外因如行业板块估值和情绪等，公司希望通过做强主业为投资者创造长期价值。2025年薪酬变动幅度亦受2024年基数低影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500034760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0042","BK0114","300146","BK0028","BK0107","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627456781","title":"汤臣倍健：拟每10股分红4.50元（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2627456781","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627456781?lang=zh_cn&edition=full","pubTime":"2026-04-13 21:20","pubTimestamp":1776086400,"startTime":"0","endTime":"0","summary":"证券日报网讯 4月13日，汤臣倍健发布公告称，公司2025年年度权益分派方案为：以公司现有总股本剔除已回购股份后的1，675，158，844股为基数，向全体股东每10股派发人民币4.50元现金（含税）。本次权益分派股权登记日为：2026年4月20日，除权除息日为：2026年4月21日。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-13/doc-inhukkny4708453.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-13/doc-inhukkny4708453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VIG","BK0107","BK0028","BK0114","BK0042","BK4588","BK0146","300146","BK0226","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437717","title":"汤臣倍健：公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627437717?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:36","pubTimestamp":1776080164,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好：贵公司保健产品齐全，想问一下，有没有减肥功效的产品？如有，请详细的介绍一下。谢谢！汤臣倍健回复：投资者您好！公司旗下“左旋肉碱茶多酚荷叶片”保健食品具有减肥的保健功能，产品详情可致电公司营养咨询热线4000916916。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300028424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0042","BK0028","BK0114","BK0107","BK0226","BK0146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437400","title":"汤臣倍健：公司已递交轻络素相关的新功能申报及产品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627437400?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:33","pubTimestamp":1776079984,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的轻络素项目进展顺利吗？公司在项目审批过程中采取过哪些积极措施？公司身为行业龙头！一个产品上市要卡8年！因为公司是民营企业所以就被打压是吗？希望公司尽快落实对投资者的承诺！汤臣倍健回复：投资者您好！公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300028310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0226","BK0028","BK0114","300146","BK0146","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625939154","title":"汤臣倍健：加速科研成果向具有核心竞争力的产品转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2625939154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625939154?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:48","pubTimestamp":1775555298,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健04月07日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2025年新品收入占比接近20%，并推出了首款自主研发的OTC产品等 。公司将围绕消费者健康需求，加速科研成果向具有核心竞争力的产品转化，深入开展重功能、新功能产品的临床研究，以市场需求与科学循证双轮驱动，实现产品力与品牌力升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0028","BK0107","BK0114","300146","BK0146","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625604790","title":"股市必读：汤臣倍健（300146）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625604790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625604790?lang=zh_cn&edition=full","pubTime":"2026-04-07 05:10","pubTimestamp":1775509826,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，汤臣倍健报收于10.76元，下跌1.65%，换手率0.99%，成交量11.15万手，成交额1.2亿元。董秘最新回复投资者： 近期媒体报道网红销冠保健品“优思益”多平台下架!作为A股主板上市公司，汤臣倍健一直强调“诚信比聪明更重要”的质量理念 。这是否会凸显像汤臣倍健这样拥有透明工厂 、严格品控体系和大量境内专利及保健食品批文的企业的长期优势？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0028","BK0146","BK0114","BK0042","BK0107","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624696106","title":"汤臣倍健：公司是此项国家标准的起草单位之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2624696106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624696106?lang=zh_cn&edition=full","pubTime":"2026-04-04 12:57","pubTimestamp":1775278626,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)04月04日在投资者关系平台上答复投资者关心的问题。投资者提问：《保健食品原料益生菌》国标公开征求意见，汤臣倍健有参与吗？汤臣倍健回复：投资者您好！公司是此项国家标准的起草单位之一，通过将多年积累的科研数据、生产质控经验与行业洞察融入标准建设工作，推动益生菌原料的质量规范与科学应用。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040400005939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0114","BK0028","BK0146","BK0042","BK0107","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847076","title":"汤臣倍健：2026年计划实现营业收入同比双位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622847076?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:12","pubTimestamp":1774606337,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问公司2026年一季度有哪些措施，可以让公司业绩增长达成双位数？汤臣倍健回复：投资者您好！2026年，公司计划实现营业收入同比双位数增长，将在多个渠道、多个重点品类进行突破。具体业务策略可查阅2025年年度报告经营计划相关内容。该目标的实现存在挑战和不确定性，不构成业绩承诺。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700039902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622784702","title":"汤臣倍健：国家尚未将“降低发生心源性猝死风险”列为可声称的保健功能","url":"https://stock-news.laohu8.com/highlight/detail?id=2622784702","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622784702?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:09","pubTimestamp":1774606149,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有哪些产品能降低发生心源性猝死风险？汤臣倍健回复：投资者您好！国家市场监督管理总局目前尚未将“降低发生心源性猝死风险”单独列为可声称的保健功能。公司始终严格遵守国家相关法律法规，所有产品的功能声称均以国家批准的保健功能为准。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700039823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","BK0114","BK0028","300146","BK0107","BK0146","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622849056","title":"汤臣倍健：公司始终重视抗衰老领域的科研探索与技术积累","url":"https://stock-news.laohu8.com/highlight/detail?id=2622849056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622849056?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:39","pubTimestamp":1774600744,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月27日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司的抗衰老的药物，保健品研究进度如何汤臣倍健回复：投资者您好！公司始终重视抗衰老领域的科研探索与技术积累。国家市场监督管理总局目前尚未将“抗衰老”单独列为可声称的保健功能。公司持续跟踪国内外前沿科学动态，将在符合法规要求的框架下，为消费者提供高品质的健康选择。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700034074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0226","BK0028","BK0114","300146","BK0146","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043867","title":"营收降、利润增，汤臣倍健“再创业”能否穿越周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043867","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622043867?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:12","pubTimestamp":1774404777,"startTime":"0","endTime":"0","summary":"营收降而利润增——这组看似矛盾的数据，恰恰勾勒出一家行业龙头在深度调整期的真实处境。全年净利润同比增长19.81%，扣非净利润同比增长9.5%，毛利率回升至67.9%。汤臣倍健正在从“全球原料采购”的渠道品牌，向“自主技术驱动”的科技品牌进化。公司坦承，2026年因在多渠道、多品类发力，销售费用率预计同比提升。汤臣倍健能否在保持规模优势的同时，实现多品牌、多品类的精细化运营，是其“再创业”战略能否成功的核心变量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774334664866830130","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["161022","300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621674530","title":"汤臣倍健：公司坚持在整体战略规划下审慎决策投资并购事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2621674530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621674530?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:51","pubTimestamp":1774356704,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健03月23日在投资者关系平台上答复投资者关心的问题。公司坚持在整体战略规划下审慎决策投资并购事项，具体请以公司公开披露信息为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400037674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0107","BK0042","BK0114","BK0226","BK0028","BK0146","300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621722507","title":"汤臣倍健：研发费用下降主要系委外研发未达预期收到供应商退款","url":"https://stock-news.laohu8.com/highlight/detail?id=2621722507","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621722507?lang=zh_cn&edition=full","pubTime":"2026-03-23 18:33","pubTimestamp":1774261994,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健03月23日在投资者关系平台上答复投资者关心的问题。公司坚定实施“科学营养”战略，持续打造科技核心竞争力优势，推动科研成果转化，研发费用下降主要系委外研发未达预期收到供应商退款，同时公司优化研发资源配置，提升研发资源投入效率所致，不影响公司科研创新能力及战略实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300031486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0028","BK0146","300146","BK0226","BK0042","BK0107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621745124","title":"股市必读：汤臣倍健年报 - 第四季度单季净利润同比增长42.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621745124","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621745124?lang=zh_cn&edition=full","pubTime":"2026-03-23 02:28","pubTimestamp":1774204090,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告汤臣倍健2025年实现主营收入62.65亿元，同比下降8.38%；归母净利润7.82亿元，同比增长19.81%；扣非净利润6.86亿元，同比增长9.49%。全年经营活动现金流净额12.14亿元，同比增长76.94%。中信证券股份有限公司关于汤臣倍健股份有限公司2025年度募集资金存放与使用情况的专项核查报告截至2025年12月31日，募集资金净额30.91亿元，累计投入12.54亿元，期末余额20.74亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300000814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621171324","title":"汤臣倍健：目前已在东南亚主要国家进行布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2621171324","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621171324?lang=zh_cn&edition=full","pubTime":"2026-03-22 12:27","pubTimestamp":1774153620,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 3月22日，汤臣倍健在业绩电话会表示，公司将以本土化需求为核心驱动国际业务扩张，目前已在东南亚主要国家进行布局，将加速扩大东南亚线下渠道覆盖，推动线上渠道实现增长突破。\n公司还表示，2026年，公司将推动传统电商、兴趣电商、跨境及商超等业务全线恢复并实现快速增长。线上渠道将作为主力增长渠道，将通过重点突破兴趣电商与跨境业务，确保传统电商持续增长驱动；线下药店渠道目标保持稳定，商超渠道则作为重点发力方向之一，将通过创新差异化产品和精细化运营实现突破。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2026/03/22/5699743814558754181.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/03/22/5699743814558754181.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1774149094129760.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1774149094129760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0226","BK0028","BK0107","BK0114","300146","BK0146","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621764028","title":"汤臣倍健(300146)2月28日股东户数6.46万户，较上期减少4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621764028","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621764028?lang=zh_cn&edition=full","pubTime":"2026-03-21 17:03","pubTimestamp":1774083811,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汤臣倍健披露，截至2026年2月28日公司股东户数为6.46万户，较12月31日减少2749.0户，减幅为4.08%。在食品加工行业个股中，汤臣倍健股东户数高于行业平均水平，截至2月28日，食品加工行业平均股东户数为3.32万户。从股价来看，2025年12月31日至2026年2月28日，汤臣倍健区间涨幅为0.42%，在此期间股东户数减少2749.0户，减幅为4.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032100011936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0042","BK0107","300146","BK0028","BK0146","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739748","title":"汤臣倍健(300146.SZ)发布2025年度业绩，归母净利润7.82亿元，增长19.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739748","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620739748?lang=zh_cn&edition=full","pubTime":"2026-03-20 21:19","pubTimestamp":1774012760,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汤臣倍健 发布2025年年度报告，该公司营业收入为62.65亿元，同比减少8.38%。归属于上市公司股东的净利润为7.82亿元，同比增长19.81%。基本每股收益为0.47元。此外，拟向全体股东每10股派发现金红利4.5元(含税)。报告期，主品牌“汤臣倍健”实现收入33.49亿元，同比下降10.38%;“健力多”实现收入7.27亿元，同比下降10.00%;“lifespace”国内产品实现收入2.14亿元，同比下降32.01%，境外LSG实现收入9.34亿元，同比上升16.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"汤臣倍健(300146.SZ)发布2025年度业绩，归母净利润7.82亿元，增长19.81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620236839","title":"汤臣倍健：坚持以消费者需求为导向","url":"https://stock-news.laohu8.com/highlight/detail?id=2620236839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620236839?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:51","pubTimestamp":1773823873,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：官媒报道，现在的国人营养过剩，满大街挺着大肚子的胖子很多，许多人都在希望减肥、少吃。请问，未来，公司在传统膳食营养产品这一块有什么变化？汤臣倍健回复：投资者您好！公司坚持以消费者需求为导向，围绕主要核心品类并结合渠道特性进行产品研发创新，为消费者提供更加多样化的产品选择。感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800028262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0028","BK0107","BK0114","BK0226","BK0042","300146"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619648839","title":"股市必读：汤臣倍健（300146）3月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2619648839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619648839?lang=zh_cn&edition=full","pubTime":"2026-03-16 02:50","pubTimestamp":1773600620,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，汤臣倍健报收于11.62元，下跌0.09%，换手率0.81%，成交量9.08万手，成交额1.06亿元。董秘最新回复投资者： 建议公司扩大核心品类研发投入 创造产品持续竞争力来扩大转化效率 牺牲短期利润来维护长期竞争力董秘： 感谢您的建议。交易信息汇总资金流向3月13日主力资金净流出369.79万元；游资资金净流入588.88万元；散户资金净流出219.09万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0107","BK0114","BK0226","BK0146","BK0028","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618594050","title":"汤臣倍健：公司将综合考虑对投资者的持续回报及公司经营发展的资金需求等确定利润分配预案","url":"https://stock-news.laohu8.com/highlight/detail?id=2618594050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618594050?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:03","pubTimestamp":1773234188,"startTime":"0","endTime":"0","summary":"证券之星消息，汤臣倍健(300146)03月11日在投资者关系平台上答复投资者关心的问题。投资者提问：公司今年业绩比去年优秀，2025年度分红应该也要大于去年，请转告大股东、董事会。谢谢汤臣倍健回复：投资者您好！公司将综合考虑对投资者的持续回报及公司经营发展的资金需求等确定利润分配预案，具体请以公司公开披露信息为准。感谢您的建议。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100037899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300146","BK0028","BK0146","BK0114","BK0042","BK0107","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776405931548,"stockEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.0885},{"period":"6month","weight":-0.0922},{"period":"1year","weight":0.0167},{"period":"ytd","weight":-0.0733}],"compareEarnings":[{"period":"1week","weight":0.0225},{"period":"1month","weight":0.0014},{"period":"3month","weight":-0.0113},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.238},{"period":"ytd","weight":0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"汤臣倍健股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"64574人(较上一季度减少4.08%)","perCapita":"17355股","listingDate":"2010-12-15","address":"广东省珠海市金湾区三灶科技工业园星汉路19号","registeredCapital":"169167万元","survey":" 汤臣倍健股份有限公司的主营业务是膳食营养补充剂的生产销售。公司的主要产品是片剂、粉剂、胶囊、其他。截至报告期末，公司已获得145项原料及配方等发明专利。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汤臣倍健,300146,汤臣倍健股票,汤臣倍健股票老虎,汤臣倍健股票老虎国际,汤臣倍健行情,汤臣倍健股票行情,汤臣倍健股价,汤臣倍健股市,汤臣倍健股票价格,汤臣倍健股票交易,汤臣倍健股票购买,汤臣倍健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汤臣倍健(300146)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汤臣倍健(300146)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}